Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects - Mario Malerba, Matteo Nardin, Giuseppe Santini,
The mechanisms of action of the different classes of bronchodilators | Download Scientific Diagram
Interpreting Recent Developments in COPD Treatments - Document - Gale Academic OneFile
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents | Respiratory Research | Full Text
Mechanisms of action of LAMAs. ACh, acetylcholine; LAMA, longacting... | Download Scientific Diagram
Dual bronchodilator therapy: A review
Single Inhaler LABA/LAMA for COPD | Semantic Scholar
Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy - ScienceDirect
jcdr-15-FE01-g001.jpg
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
JCM | Free Full-Text | LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
Mechanisms of bronchodilatory action of antimuscarinic agents and... | Download Scientific Diagram
Frontiers | Single Inhaler LABA/LAMA for COPD
Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy - ScienceDirect
Single Inhaler LABA/LAMA for COPD. - Abstract - Europe PMC
When to use the new LAB + LAMA combinations ? - ppt video online download
Addressing unmet needs in the treatment of COPD | European Respiratory Society
Pharmacologic rationale underlying the therapeutic effects of tiotropi | TCRM
Triple Therapy in COPD | Bentham Science
Novel bronchodilators for the treatment of chronic obstructive pulmonary disease: Trends in Pharmacological Sciences
The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review | European Respiratory Society
Inhaled Medicines: Past, Present, and Future | Pharmacological Reviews
Frontiers | The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD
Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. - Abstract - Europe PMC
Understanding the role of long-acting muscarinic antagonists in asthma treatment - ScienceDirect
